Protective role of chronic statin therapy in reducing myocardial damage during percutaneous coronary intervention

Journal of Cardiovascular Medicine

Volumn 7, Issue 6, 2006, Pages 416-421

  Auguadro, Carla ^a   Manfredi, Mariella ^a   Scalise, Filippo ^a   Mortara, Andrea ^a   Specchia, Giuseppe ^a  

^a Policlinico di Monza   (Italy)

Author keywords

Myocardial damage; Percutaneous coronary intervention; Statins; Troponin I

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; GLUCOSE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL; TROPONIN I;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; CLINICAL FEATURE; CORONARY STENT; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG USE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INJURY SEVERITY; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; REPERFUSION INJURY; STENT; VASCULAR DISEASE;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CREATINE KINASE; CREATINE KINASE, MB FORM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TROPONIN I;

EID: 33746596228     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000228692.25205.86     Document Type: Article

References (42)

1. Mongiardo A, Ferraro A, Ceravolo R, Mascaro G, Curcio A, Campopiano E, et al. Mechanism of troponin and CK-MB release after percutaneous coronary interventions. Ital Heart J Suppl 2002; 3:270-274.
2. Wu CJ, Liang HL, Chiou KR, Mar GY, Tseng CJ, Lin SL, et al. Significance of cardiac troponin I and creatine kinase release after coronary intervention. Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64:343-350.
3. Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Detection of minor myocardial injury after successful percutaneous transluminal coronary angioplasty with or without stenting. Med Sci Monit 2000; 6:708-712.
4. Fuchs S, Kornowski R, Mehran R, Lansky AJ, Satler LF, Pichard AD, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000; 85:1077-1082.
5. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535-1542.
6. Garbarz E, Iung B, Lefevre G, Makita Y, Farah B, Michaud P, et al. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol 1999; 84:515-518.
7. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000; 85:962-968.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335:1001-1009.
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
11. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD, for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452.
12. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial. JAMA 2001; 285:1711-1718.
13. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430-436.
14. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357:1063-1068.
15. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105:691-696.
16. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38:2006-2012.
17. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003; 145:522-528.
18. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2:208-217.
19. Bickel C, Rupprecht HJ, Blankenberg S, Espinola-Klein C, Rippin G, Hafner G, et al., for the AtheroGene Group. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002; 82:25-31.
20. Merten M, Dong JF, Lopez JA, Thiagarajan P. Cholesterol sulfate: a new adhesive molecule for platelets. Circulation 2001; 103:2032-2034.
21. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15:247-251.
22. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172-3177.
23. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99:3227-3233.
24. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-1935.
25. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet1999; 353:118-119.
26. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Statins and C-reactive protein [letter]. Lancet 1999; 353:1274.
27. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-235.
28. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98:839-844.
29. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001; 173:139-143.
30. Wolfrum S, Grimm M, Heidbreder M, Dendorfer A, Katus HA, Liao JK, et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 2003; 41:474-480.
31. Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J 2001; 15:2530-2532.
32. Di Napoli P, Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001; 51:283-293.
33. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106:2180-2183.
34. Halligan S, Hermann J, Lennon R, Pumper G, Higano S, Methew Verghese, et al. Prior treatment with statins decreases cardiac biomarker rise in patients undergoing percutaneous coronary interventions [abstract]. J Am Coll Cardiol 2003; 41 (suppl A):45A.
35. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, for the ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110:674-678.
36. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, et al., for the Italian Atherosclerosis, Thrombosis and Vascular Biology and Society for Invasive Cardiology-GISE Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 26:1494-1498.
37. Gaspardone A, Versaci F, Proietti I, Tomai F, Altamura L, Skossyreva O, et al. Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Am J Cardiol 2002; 90:786-789.
38. Ott I, Neumann FJ, Kenngott S, Gawaz M, Schomig A. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol 1998; 82:938-942.
39. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996; 94:2064-2071.
40. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98:224-233.
41. Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys PW, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995; 91:1320-1325.
42. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001; 173:139-143.